Improved quality of life following treatment with mogamulizumab in MF/SS

Following treatment with mogamulizumab, patients with mycosis fungoides (MF) and Sézary syndrome (SS) reported improved skin symptoms, sleep problems, and body temperature regulation within 4 weeks of treatment. These improvements were sustained throughout 24 weeks of follow-up. These were the main results of an interim analysis of the PROSPER study.

The prospective, observational PROSPER study aims to describe changes in symptoms and health-related quality of life (HRQoL) following mogamulizumab treatment in patients with MF or SS. The results of the first 20 patients were presented by Prof. Julia Scarisbrick (University of Birmingham, UK) [1]. Patients rated the severity of their skin symptoms using 0-10 numerical rating scales, and sleep problems and difficulties regulating body temperature with a Likert scale. Patients completed the Brief Fatigue Inventory (BFI) and the MF/SS CTCL-QoL every 12 weeks.

Mean age was 63 years, 10 patients were male and 10 female, 12 (60%) had SS, 18 (90%) had advanced disease. Skin itch was reported as the worst skin symptom at baseline. All 4 measured skin symptoms showed improvement within 4 weeks after starting mogamulizumab, which was maintained at week 24:

• skin itch: from 6.63 to 4.94;
• skin flaking: from 5.89 to 3.75;
• skin pain: from 4.00 to 2.63;
• skin redness: from 6.21 to 4.13.

Mean Brief Fatigue Inventory global score went down from 3.76 at baseline to 3.05 at week 24. The proportion of patients reporting that sleep problems and problems with body temperature occurred frequently or every night/always, decreased from 56% and 48%, respectively, to 19% and 12%. The MF/SS-CTCL-QoL mean score decreased from moderate interference at baseline and week 12 to mild interference at week 24. The MF/SS-CTCL-QoL mean score was 112.71 at baseline and 105.33 after 24 weeks. The proportion of patients reporting moderate or substantial MF/SS-CTCL-QoL burden decreased from 76% to 44%.

1. Scarisbrick J, et al. Patient-reported symptoms and HRQL of MF and SS patients receiving mogamulizumab over 24 weeks: interim results from the PROSPER study. Abstract A-201, EORTC-CLTG 2024, 9-11 October 2024, Lausanne, Switserland.

Posted on 14 October 2024